TY  - JOUR
A1  - Grohe, Christian
A1  - Gleiber, Wolfgang
A1  - Haas, Siegfried
A1  - Losem, Christoph
A1  - Mueller-Huesmann, Harald
A1  - Schulze, Mathias
A1  - Franke, Christian
A1  - Basara, Nadezda
A1  - Atz, Judith
A1  - Kaiser, Rolf
T1  - Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma
T2  - Future oncology
N2  - Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARGADO is a prospective, noninterventional study. We describe initial data from a cohort of 22 patients who received nintedanib plus docetaxel after chemotherapy and ICI therapy. Results: Median progression-free survival with nintedanib plus docetaxel was 5.5 months (95% CI: 1.9–8.7 months). The objective response rate was 7/12 (58%) and the disease control rate was 10/12 (83%). Data for overall survival rate 12 months after the start of treatment (primary end point) are not yet mature and are not reported. Of 22 patients, 73% experienced drug-related adverse events; adverse events led to treatment discontinuation in 32% of patients. Conclusion: These data highlight the potential clinical benefit of nintedanib plus docetaxel in patients who failed prior ICI therapy.
Trial registration number: NCT02392455
KW  - angio-immunogenic switch
KW  - docetaxel
KW  - nintedanib
KW  - non-small-cell lung cancer
KW  - tumor microenvironment
KW  - VARGADO
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/47528
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-475281
N1  - This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
VL  - 15
IS  - 23
SP  - 2699
EP  - 2706
PB  - London
CY  - Future Medicine Ltd
ER  -